Key terms

About IBRX

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IBRX news

Apr 17 5:26pm ET ImmunityBio files automatic mixed securities shelf by TipRanks Apr 12 3:16pm ET ImmunityBio put volume heavy and directionally bearish by TipRanks Apr 11 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 01 2:46pm ET ImmunityBio call volume above normal and directionally bullish by TipRanks Apr 01 8:46am ET Largest borrow rate increases among liquid names by TipRanks Mar 25 6:50am ET Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL) by TipRanks Mar 25 6:33am ET ImmunityBio price target raised to $5 from $4 at Piper Sandler by TipRanks Mar 15 11:05am ET ImmunityBio call volume above normal and directionally bullish by TipRanks Mar 12 8:45am ET Largest borrow rate increases among liquid names by TipRanks Mar 08 8:45am ET Largest borrow rate increases among liquid names by TipRanks Mar 05 9:26am ET ImmunityBio publishes data showing potential to reduce HIV load by TipRanks Feb 29 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 28 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 26 9:40am ET Unusually active option classes on open February 26th by TipRanks Feb 26 6:12am ET ImmunityBio Boosts Executive Compensation and Sets Incentives by TipRanks Feb 21 9:20am ET ImmunityBio announces full accrual of first two phases of cancer vaccine trial by TipRanks Feb 21 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 12 8:45am ET Largest borrow rate increases among liquid names by TipRanks Feb 05 9:29am ET ImmunityBio: PROs IN QUILT 3.032 trial indicate stability of physical function by TipRanks Feb 02 8:45am ET Largest borrow rate increases among liquid names by TipRanks
Mar 15 12:51pm ET Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm by Newsfile

IBRX Financials

1-year income & revenue

Key terms

IBRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IBRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming